S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
NASDAQ:OABI

OmniAb (OABI) Stock Forecast, Price & News

$4.25
+0.08 (+1.92%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$4.13
$4.27
50-Day Range
$3.21
$4.31
52-Week Range
$1.91
$10.50
Volume
279,000 shs
Average Volume
639,582 shs
Market Capitalization
$491.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

OmniAb MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
135.3% Upside
$10.00 Price Target
Short Interest
Bearish
4.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of OmniAb in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$230,950 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.37) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

803rd out of 1,010 stocks

Commercial Physical Research Industry

14th out of 16 stocks


OABI stock logo

About OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

OABI Stock News Headlines

OmniAb (NASDAQ:OABI) Trading 9% Higher
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
SVB Securities Remains a Buy on OmniAb (OABI)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
OmniAb (OABI) Scheduled to Post Earnings on Thursday
Analyzing OmniAb (NASDAQ:OABI) and Medpace (NASDAQ:MEDP)
Brokerages Set OmniAb, Inc. (NASDAQ:OABI) PT at $10.29
Analyzing MaxCyte (NASDAQ:MXCT) and OmniAb (NASDAQ:OABI)
OmniAb Full Year 2022 Earnings: Beats Expectations
See More Headlines
Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

OABI Company Calendar

Last Earnings
3/30/2023
Today
5/29/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OABI
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+135.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-22,330,000.00
Pretax Margin
-47.77%

Debt

Sales & Book Value

Annual Sales
$59.08 million
Book Value
$2.96 per share

Miscellaneous

Free Float
N/A
Market Cap
$491.30 million
Optionable
Not Optionable
Beta
-0.88

Key Executives

  • Mr. Matthew W. Foehr (Age 50)
    Pres, CEO & Director
    Comp: $909k
  • Mr. Charles S. Berkman J.D. (Age 54)
    Chief Legal Officer & Sec.
    Comp: $665.83k
  • Mr. Kurt A. Gustafson (Age 55)
    Exec. VP of Fin. & CFO
  • Dr. Bill Harriman Ph.D.
    Sr. VP of Antibody Discovery
  • Ms. Marie-Cecile van de Lavoir D.V.M.
    Ph.D., Sr. VP of Technical Operations & Genetics
  • Dr. Christel Iffland Ph.D.
    Sr. VP of Antibody Technologies
  • Dr. Douglas S. Krafte Ph.D. (Age 65)
    Sr. VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
  • Ms. Donna Ventura CPA
    Sr. VP of Corp. Controller













OABI Stock - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OABI shares.
View OABI analyst ratings
or view top-rated stocks.

What is OmniAb's stock price forecast for 2023?

9 brokerages have issued 1 year price targets for OmniAb's stock. Their OABI share price forecasts range from $6.00 to $13.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts price targets for OABI
or view top-rated stocks among Wall Street analysts.

How have OABI shares performed in 2023?

OmniAb's stock was trading at $3.60 at the beginning of 2023. Since then, OABI shares have increased by 18.1% and is now trading at $4.25.
View the best growth stocks for 2023 here
.

When is OmniAb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our OABI earnings forecast
.

How were OmniAb's earnings last quarter?

OmniAb, Inc. (NASDAQ:OABI) posted its quarterly earnings results on Thursday, March, 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. The firm had revenue of $35.35 million for the quarter, compared to the consensus estimate of $24.73 million.

What ETF holds OmniAb's stock ?

First Trust Multi-Manager Small Cap Opportunities ETF holds 299 shares of OABI stock, representing 0.04% of its portfolio.

What is OmniAb's stock symbol?

OmniAb trades on the NASDAQ under the ticker symbol "OABI."

Who are OmniAb's major shareholders?

OmniAb's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.94%), Macquarie Group Ltd. (3.27%), First Sabrepoint Capital Management LP (2.77%), Rice Hall James & Associates LLC (2.44%), William Blair Investment Management LLC (2.38%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OmniAb's stock price today?

One share of OABI stock can currently be purchased for approximately $4.25.

How much money does OmniAb make?

OmniAb (NASDAQ:OABI) has a market capitalization of $491.30 million and generates $59.08 million in revenue each year.

How can I contact OmniAb?

OmniAb's mailing address is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.omniab.com. The company can be reached via phone at 510-250-7800 or via email at investors@omniab.com.

This page (NASDAQ:OABI) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -